Vaccine development to prevent Staphylococcus aureus surgical-site infections.
Identifieur interne : 001295 ( PubMed/Curation ); précédent : 001294; suivant : 001296Vaccine development to prevent Staphylococcus aureus surgical-site infections.
Auteurs : N. Mohamed [États-Unis] ; M Y Wang [États-Unis] ; J-C Le Huec [France] ; U. Liljenqvist [Allemagne] ; I L Scully [États-Unis] ; J. Baber [Australie] ; E. Begier [États-Unis] ; K U Jansen [États-Unis] ; A. Gurtman [États-Unis] ; A S Anderson [États-Unis]Source :
- The British journal of surgery [ 1365-2168 ] ; 2017.
Descripteurs français
- KwdFr :
- Antibioprophylaxie, Essais cliniques comme sujet, Humains, Infection de plaie opératoire (), Infection de plaie opératoire (microbiologie), Infections à staphylocoques (), Lutte contre l'infection (), Résistance bactérienne aux médicaments, Staphylococcus aureus (pathogénicité), Vaccins antistaphylococciques (usage thérapeutique).
- MESH :
- microbiologie : Infection de plaie opératoire.
- pathogénicité : Staphylococcus aureus.
- usage thérapeutique : Vaccins antistaphylococciques.
- Antibioprophylaxie, Essais cliniques comme sujet, Humains, Infection de plaie opératoire, Infections à staphylocoques, Lutte contre l'infection, Résistance bactérienne aux médicaments.
English descriptors
- KwdEn :
- Antibiotic Prophylaxis, Clinical Trials as Topic, Drug Resistance, Bacterial, Humans, Infection Control (methods), Staphylococcal Infections (prevention & control), Staphylococcal Vaccines (therapeutic use), Staphylococcus aureus (pathogenicity), Surgical Wound Infection (microbiology), Surgical Wound Infection (prevention & control).
- MESH :
- chemical , therapeutic use : Staphylococcal Vaccines.
- methods : Infection Control.
- microbiology : Surgical Wound Infection.
- pathogenicity : Staphylococcus aureus.
- prevention & control : Staphylococcal Infections, Surgical Wound Infection.
- Antibiotic Prophylaxis, Clinical Trials as Topic, Drug Resistance, Bacterial, Humans.
Abstract
Staphylococcus aureus surgical-site infections (SSIs) are a major cause of poor health outcomes, including mortality, across surgical specialties. Despite current advances as a result of preventive interventions, the disease burden of S. aureus SSI remains high, and increasing antibiotic resistance continues to be a concern. Prophylactic S. aureus vaccines may represent an opportunity to prevent SSI.
DOI: 10.1002/bjs.10454
PubMed: 28121039
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001317
Links to Exploration step
pubmed:28121039Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Vaccine development to prevent Staphylococcus aureus surgical-site infections.</title><author><name sortKey="Mohamed, N" sort="Mohamed, N" uniqKey="Mohamed N" first="N" last="Mohamed">N. Mohamed</name><affiliation wicri:level="1"><nlm:affiliation>Pfizer Vaccine Research and Development, Pearl River, New York, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer Vaccine Research and Development, Pearl River, New York</wicri:regionArea></affiliation></author><author><name sortKey="Wang, M Y" sort="Wang, M Y" uniqKey="Wang M" first="M Y" last="Wang">M Y Wang</name><affiliation wicri:level="1"><nlm:affiliation>Departments of Neurological Surgery and Rehabilitation Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Departments of Neurological Surgery and Rehabilitation Medicine, University of Miami Miller School of Medicine, Miami, Florida</wicri:regionArea></affiliation></author><author><name sortKey="Le Huec, J C" sort="Le Huec, J C" uniqKey="Le Huec J" first="J-C" last="Le Huec">J-C Le Huec</name><affiliation wicri:level="1"><nlm:affiliation>Spine Unit 2, Surgical Research Laboratory, Bordeaux University Hospital, Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Spine Unit 2, Surgical Research Laboratory, Bordeaux University Hospital, Bordeaux</wicri:regionArea></affiliation></author><author><name sortKey="Liljenqvist, U" sort="Liljenqvist, U" uniqKey="Liljenqvist U" first="U" last="Liljenqvist">U. Liljenqvist</name><affiliation wicri:level="1"><nlm:affiliation>Department of Spine Surgery, St Franziskus Hospital Muenster, Münster, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Spine Surgery, St Franziskus Hospital Muenster, Münster</wicri:regionArea></affiliation></author><author><name sortKey="Scully, I L" sort="Scully, I L" uniqKey="Scully I" first="I L" last="Scully">I L Scully</name><affiliation wicri:level="1"><nlm:affiliation>Pfizer Vaccine Research and Development, Pearl River, New York, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer Vaccine Research and Development, Pearl River, New York</wicri:regionArea></affiliation></author><author><name sortKey="Baber, J" sort="Baber, J" uniqKey="Baber J" first="J" last="Baber">J. Baber</name><affiliation wicri:level="1"><nlm:affiliation>Pfizer Vaccine Clinical Research and Development, Sydney, New South Wales, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Pfizer Vaccine Clinical Research and Development, Sydney, New South Wales</wicri:regionArea></affiliation></author><author><name sortKey="Begier, E" sort="Begier, E" uniqKey="Begier E" first="E" last="Begier">E. Begier</name><affiliation wicri:level="1"><nlm:affiliation>Pfizer Vaccine Clinical Research and Development, Pearl River, New York, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer Vaccine Clinical Research and Development, Pearl River, New York</wicri:regionArea></affiliation></author><author><name sortKey="Jansen, K U" sort="Jansen, K U" uniqKey="Jansen K" first="K U" last="Jansen">K U Jansen</name><affiliation wicri:level="1"><nlm:affiliation>Pfizer Vaccine Research and Development, Pearl River, New York, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer Vaccine Research and Development, Pearl River, New York</wicri:regionArea></affiliation></author><author><name sortKey="Gurtman, A" sort="Gurtman, A" uniqKey="Gurtman A" first="A" last="Gurtman">A. Gurtman</name><affiliation wicri:level="1"><nlm:affiliation>Pfizer Vaccine Clinical Research and Development, Pearl River, New York, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer Vaccine Clinical Research and Development, Pearl River, New York</wicri:regionArea></affiliation></author><author><name sortKey="Anderson, A S" sort="Anderson, A S" uniqKey="Anderson A" first="A S" last="Anderson">A S Anderson</name><affiliation wicri:level="1"><nlm:affiliation>Pfizer Vaccine Research and Development, Pearl River, New York, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer Vaccine Research and Development, Pearl River, New York</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28121039</idno><idno type="pmid">28121039</idno><idno type="doi">10.1002/bjs.10454</idno><idno type="wicri:Area/PubMed/Corpus">001317</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001317</idno><idno type="wicri:Area/PubMed/Curation">001295</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001295</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Vaccine development to prevent Staphylococcus aureus surgical-site infections.</title><author><name sortKey="Mohamed, N" sort="Mohamed, N" uniqKey="Mohamed N" first="N" last="Mohamed">N. Mohamed</name><affiliation wicri:level="1"><nlm:affiliation>Pfizer Vaccine Research and Development, Pearl River, New York, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer Vaccine Research and Development, Pearl River, New York</wicri:regionArea></affiliation></author><author><name sortKey="Wang, M Y" sort="Wang, M Y" uniqKey="Wang M" first="M Y" last="Wang">M Y Wang</name><affiliation wicri:level="1"><nlm:affiliation>Departments of Neurological Surgery and Rehabilitation Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Departments of Neurological Surgery and Rehabilitation Medicine, University of Miami Miller School of Medicine, Miami, Florida</wicri:regionArea></affiliation></author><author><name sortKey="Le Huec, J C" sort="Le Huec, J C" uniqKey="Le Huec J" first="J-C" last="Le Huec">J-C Le Huec</name><affiliation wicri:level="1"><nlm:affiliation>Spine Unit 2, Surgical Research Laboratory, Bordeaux University Hospital, Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Spine Unit 2, Surgical Research Laboratory, Bordeaux University Hospital, Bordeaux</wicri:regionArea></affiliation></author><author><name sortKey="Liljenqvist, U" sort="Liljenqvist, U" uniqKey="Liljenqvist U" first="U" last="Liljenqvist">U. Liljenqvist</name><affiliation wicri:level="1"><nlm:affiliation>Department of Spine Surgery, St Franziskus Hospital Muenster, Münster, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Spine Surgery, St Franziskus Hospital Muenster, Münster</wicri:regionArea></affiliation></author><author><name sortKey="Scully, I L" sort="Scully, I L" uniqKey="Scully I" first="I L" last="Scully">I L Scully</name><affiliation wicri:level="1"><nlm:affiliation>Pfizer Vaccine Research and Development, Pearl River, New York, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer Vaccine Research and Development, Pearl River, New York</wicri:regionArea></affiliation></author><author><name sortKey="Baber, J" sort="Baber, J" uniqKey="Baber J" first="J" last="Baber">J. Baber</name><affiliation wicri:level="1"><nlm:affiliation>Pfizer Vaccine Clinical Research and Development, Sydney, New South Wales, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Pfizer Vaccine Clinical Research and Development, Sydney, New South Wales</wicri:regionArea></affiliation></author><author><name sortKey="Begier, E" sort="Begier, E" uniqKey="Begier E" first="E" last="Begier">E. Begier</name><affiliation wicri:level="1"><nlm:affiliation>Pfizer Vaccine Clinical Research and Development, Pearl River, New York, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer Vaccine Clinical Research and Development, Pearl River, New York</wicri:regionArea></affiliation></author><author><name sortKey="Jansen, K U" sort="Jansen, K U" uniqKey="Jansen K" first="K U" last="Jansen">K U Jansen</name><affiliation wicri:level="1"><nlm:affiliation>Pfizer Vaccine Research and Development, Pearl River, New York, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer Vaccine Research and Development, Pearl River, New York</wicri:regionArea></affiliation></author><author><name sortKey="Gurtman, A" sort="Gurtman, A" uniqKey="Gurtman A" first="A" last="Gurtman">A. Gurtman</name><affiliation wicri:level="1"><nlm:affiliation>Pfizer Vaccine Clinical Research and Development, Pearl River, New York, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer Vaccine Clinical Research and Development, Pearl River, New York</wicri:regionArea></affiliation></author><author><name sortKey="Anderson, A S" sort="Anderson, A S" uniqKey="Anderson A" first="A S" last="Anderson">A S Anderson</name><affiliation wicri:level="1"><nlm:affiliation>Pfizer Vaccine Research and Development, Pearl River, New York, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer Vaccine Research and Development, Pearl River, New York</wicri:regionArea></affiliation></author></analytic><series><title level="j">The British journal of surgery</title><idno type="eISSN">1365-2168</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibiotic Prophylaxis</term><term>Clinical Trials as Topic</term><term>Drug Resistance, Bacterial</term><term>Humans</term><term>Infection Control (methods)</term><term>Staphylococcal Infections (prevention & control)</term><term>Staphylococcal Vaccines (therapeutic use)</term><term>Staphylococcus aureus (pathogenicity)</term><term>Surgical Wound Infection (microbiology)</term><term>Surgical Wound Infection (prevention & control)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antibioprophylaxie</term><term>Essais cliniques comme sujet</term><term>Humains</term><term>Infection de plaie opératoire ()</term><term>Infection de plaie opératoire (microbiologie)</term><term>Infections à staphylocoques ()</term><term>Lutte contre l'infection ()</term><term>Résistance bactérienne aux médicaments</term><term>Staphylococcus aureus (pathogénicité)</term><term>Vaccins antistaphylococciques (usage thérapeutique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Staphylococcal Vaccines</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Infection Control</term></keywords><keywords scheme="MESH" qualifier="microbiologie" xml:lang="fr"><term>Infection de plaie opératoire</term></keywords><keywords scheme="MESH" qualifier="microbiology" xml:lang="en"><term>Surgical Wound Infection</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Staphylococcus aureus</term></keywords><keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Staphylococcus aureus</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Staphylococcal Infections</term><term>Surgical Wound Infection</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Vaccins antistaphylococciques</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Antibiotic Prophylaxis</term><term>Clinical Trials as Topic</term><term>Drug Resistance, Bacterial</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Antibioprophylaxie</term><term>Essais cliniques comme sujet</term><term>Humains</term><term>Infection de plaie opératoire</term><term>Infections à staphylocoques</term><term>Lutte contre l'infection</term><term>Résistance bactérienne aux médicaments</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Staphylococcus aureus surgical-site infections (SSIs) are a major cause of poor health outcomes, including mortality, across surgical specialties. Despite current advances as a result of preventive interventions, the disease burden of S. aureus SSI remains high, and increasing antibiotic resistance continues to be a concern. Prophylactic S. aureus vaccines may represent an opportunity to prevent SSI.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28121039</PMID><DateCreated><Year>2017</Year><Month>01</Month><Day>25</Day></DateCreated><DateCompleted><Year>2017</Year><Month>04</Month><Day>03</Day></DateCompleted><DateRevised><Year>2017</Year><Month>08</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1365-2168</ISSN><JournalIssue CitedMedium="Internet"><Volume>104</Volume><Issue>2</Issue><PubDate><Year>2017</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The British journal of surgery</Title><ISOAbbreviation>Br J Surg</ISOAbbreviation></Journal><ArticleTitle>Vaccine development to prevent Staphylococcus aureus surgical-site infections.</ArticleTitle><Pagination><MedlinePgn>e41-e54</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/bjs.10454</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Staphylococcus aureus surgical-site infections (SSIs) are a major cause of poor health outcomes, including mortality, across surgical specialties. Despite current advances as a result of preventive interventions, the disease burden of S. aureus SSI remains high, and increasing antibiotic resistance continues to be a concern. Prophylactic S. aureus vaccines may represent an opportunity to prevent SSI.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A review of SSI pathophysiology was undertaken in the context of evaluating new approaches to developing a prophylactic vaccine to prevent S. aureus SSI.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A prophylactic vaccine ideally would provide protective immunity at the time of the surgical incision to prevent initiation and progression of infection. Although the pathogenicity of S. aureus is attributed to many virulence factors, previous attempts to develop S. aureus vaccines targeted only a single virulence mechanism. The field has now moved towards multiple-antigen vaccine strategies, and promising results have been observed in early-phase clinical studies that supported the recent initiation of an efficacy trial to prevent SSI.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">There is an unmet medical need for novel S. aureus SSI prevention measures. Advances in understanding of S. aureus SSI pathophysiology could lead to the development of effective and safe prophylactic multiple-antigen vaccines to prevent S. aureus SSI.</AbstractText><CopyrightInformation>© 2017 BJS Society Ltd Published by John Wiley & Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mohamed</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Pfizer Vaccine Research and Development, Pearl River, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>M Y</ForeName><Initials>MY</Initials><AffiliationInfo><Affiliation>Departments of Neurological Surgery and Rehabilitation Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Huec</LastName><ForeName>J-C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Spine Unit 2, Surgical Research Laboratory, Bordeaux University Hospital, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liljenqvist</LastName><ForeName>U</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Spine Surgery, St Franziskus Hospital Muenster, Münster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scully</LastName><ForeName>I L</ForeName><Initials>IL</Initials><AffiliationInfo><Affiliation>Pfizer Vaccine Research and Development, Pearl River, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baber</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Pfizer Vaccine Clinical Research and Development, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Begier</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Pfizer Vaccine Clinical Research and Development, Pearl River, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jansen</LastName><ForeName>K U</ForeName><Initials>KU</Initials><AffiliationInfo><Affiliation>Pfizer Vaccine Research and Development, Pearl River, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gurtman</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pfizer Vaccine Clinical Research and Development, Pearl River, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>A S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Pfizer Vaccine Research and Development, Pearl River, New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Surg</MedlineTA><NlmUniqueID>0372553</NlmUniqueID><ISSNLinking>0007-1323</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013209">Staphylococcal Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019072" MajorTopicYN="N">Antibiotic Prophylaxis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024881" MajorTopicYN="N">Drug Resistance, Bacterial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017053" MajorTopicYN="N">Infection Control</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013203" MajorTopicYN="N">Staphylococcal Infections</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013209" MajorTopicYN="N">Staphylococcal Vaccines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013211" MajorTopicYN="N">Staphylococcus aureus</DescriptorName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013530" MajorTopicYN="N">Surgical Wound Infection</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="Y">microbiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>08</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>11</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>1</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>1</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28121039</ArticleId><ArticleId IdType="doi">10.1002/bjs.10454</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001295 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001295 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:28121039
|texte= Vaccine development to prevent Staphylococcus aureus surgical-site infections.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:28121039" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |